Synonyms: RP-3500 | RP3500
Compound class:
Synthetic organic
Comment: RP-3500 is a clinical lead, selective ATR (Ataxia telangiectasia and Rad3-related) serine/threonine kinase inhibitor that was developed as a novel oncology therapeutic [1]. We matched RP-3500's chemical structure to the INN 'camonsertib' that was included in the WHO's proposed INN list 127 (21 July 2022).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
RP-3500 is selective for ATR and it inhibits ATR kinase activity in biochemical and cell-based assays. It exhibits 30-fold selectivity over mammalian target of rapamycin (mTOR) and >2,000-fold selectivity over ataxia telangiectasia mutated (ATM) kinase, DNA-dependent protein kinase (DNA-PK), and phosphatidylinositol 3-kinase alpha (PI3Kα) in vitro [1]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|